To ascertain the binding affinities and mode of interactions of free linalool and its synthesized nanoconjugates as inhibitors, docking studies were performed on six GBM targets with the following PDB IDs: EGFR (PDB ID: 4HJO), PD-L1 (PDB ID: 5N2F), TP53 (PDB ID: 7B49), CDK6 (PDB ID: 6OQL), CD8A (PDB ID: 2HP4), and PTEN (PDB ID: 1D5R). The gene discussed is CD8A; the disease is glioblastoma.